TG Therapeutics (NASDAQ:TGTX) Stock Price Down 8.7%

TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) shares traded down 8.7% during mid-day trading on Friday . The stock traded as low as $7.60 and last traded at $7.60. 133,617 shares were traded during mid-day trading, a decline of 96% from the average session volume of 3,114,533 shares. The stock had previously closed at $8.32.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of TG Therapeutics in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $21.25.

TG Therapeutics Price Performance

The firm has a market cap of $1.16 billion, a PE ratio of -4.50 and a beta of 2.12. The stock’s fifty day moving average price is $6.31 and its 200-day moving average price is $6.03. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.02 and a quick ratio of 5.02.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds have recently modified their holdings of the company. Fifth Third Bancorp purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $27,000. Liberty One Investment Management LLC boosted its stake in TG Therapeutics by 3,697.6% during the second quarter. Liberty One Investment Management LLC now owns 4,709 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 4,585 shares during the period. Lazard Asset Management LLC purchased a new position in TG Therapeutics during the first quarter worth about $60,000. Allspring Global Investments Holdings LLC boosted its stake in TG Therapeutics by 517.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 6,603 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 5,533 shares during the period. Finally, Great West Life Assurance Co. Can purchased a new position in TG Therapeutics during the third quarter worth about $40,000. Hedge funds and other institutional investors own 72.64% of the company’s stock.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Further Reading

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.